By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Prosensa Holding B.V. ("Prosensa" or the "Company") (NASDAQ: RNA) concerning possible violations of federal securities laws. Investors with losses of $100,000 or more are encouraged to contact the firm for more information (see also Glancy Binkow & Goldberg LLP).
Please contact us at (212) 682-5340, Toll-Free at (888) 773-9224, or at email@example.com to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
Prosensa is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders, primarily rare neuromuscular and neurodegenerative disorders, including myotonic dystrophy, Huntington's disease and Duchenne muscular dystrophy, or DMD. The Company's lead RNA-based product candidate is drisapersen, a treatment for muscle wasting caused by DMD.
The investigation is related to allegations that the Company's Registration Statement and Prospectus issued in connection with Prosensa'sJune 28, 2013, initial public offering were materially false and misleading. Specifically, the investigation focuses on allegations that the Registration Statement and Prospectus misrepresented or failed to disclose material facts concerning the efficacy of drisapersen and the prospects for its marketing approval.
If you purchased Prosensa shares, if you have information or would like to learn more about these claims or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to firstname.lastname@example.org, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Keywords for this news article include: Treatment, Glancy Binkow & Goldberg LLP.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC